23 Apr 2014 07:00
23 April 2014
Plethora Solutions Holdings PLC
("Plethora" or the "Company")
Company update
Annual Financial Report for the year ended 31 December 2013 and notice of AGM
Plethora Solutions Holdings plc (AIM:PLE) announces that the Company will post the Annual Report and Accounts to shareholders on 25 April 2014 together with the notice of the Annual General Meeting which will take place at 10.00 am on 10 June 2014 at the offices of Daniel Stewart, Becket House, 36 Old Jewry, London, ECR 8DD.
The Annual Report and Accounts for the year ended 31 December 2013 and Notice of AGM are now available on the Company's website at www.plethorasolutions.co.uk.
-Ends-
Enquiries:
Plethora Solutions Jim Mellon, Chairman Jamie Gibson, CEO Mike Wyllie, CSO Mike Collis, CFO Greg Bailey, NXD
| Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) David Hart / Ciaran Walsh (Nomad) Martin Lampshire (Broker)
| Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce William Lynne |
Tel: +44(0) 20 7947 4350 Tel: +44(0) 20 7947 4361
|
Britton Financial PR Tim Blackstone | Tel: + 44 (0) 20 7242 9786 +44 (0) 7957 140416 |
About Plethora:
Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk
Plethora is focussed on seeking to launch PSD502 for the treatment of premature ejaculation.
About PSD502 & Premature Ejaculation:
PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. The Company anticipates launch in 2014.
Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.
In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.